Investors
 | Webcast Depomed at Wells Fargo Health Care Conference (Live) 06/19/13 at 11:15 a.m. ET |
| Webcast Depomed at Jefferies 2013 Global Healthcare Conference (Replay) 06/03/13 at 4:30 p.m. ET |
| Webcast Depomed at UBS Global Healthcare Conference (Replay) 05/21/13 at 10:00 a.m. ET |
Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. We currently sell Gralise® (gabapentin), a once-daily product for the management of postherpetic neuralgia, and Zipsor® (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain. We actively seek to expand our product portfolio through in-licensing, acquiring or obtaining co-promotion rights to commercially available products or late-stage product candidates that could be marketed and sold effectively with our existing products through our sales and marketing capability.
We also receive royalties on three products marketed by licensees of our Accuform ® gastroretentive drug delivery technology: Glumetza® commercialized by Santarus, Inc., Janumet XR® commercialized by Merck & Co., Inc. and Nucynta ER® commercialized by Janssen Pharmaceuticals, Inc. We have license and development arrangements relating to product candidates that use our Acuform® delivery technology with Covidien, Ltd., Boehringer Ingelheim International GMBH, Ironwood Pharmaceuticals, Inc., and Janssen Pharmaceutica N.V.
| Recent News | > MORE |
 |
| Upcoming and Recent Events | > MORE |
| ||||||||||||||||||||||||||||
